Personalized Medicine

(ISSN: 1741-0541)

Mission Statement

Personalized Medicine translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved – academic, clinical and industrial researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. The journal addresses scientific, commercial and policy issues in personalized medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.

Coverage includes:

  • Advances in molecular diagnostics
  • Biochip/microarray technologies
  • Biological therapies or vaccine approaches at specific genetic and immunologic targets
  • Cost-benefit issues for personalized medicine
  • Ethics in personalized medicine
  • Impact of personalized medicine on healthcare and the pharmaceutical industry
  • Impact of the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics and pharmacoproteomics
  • Incorporation of genetic analysis in clinical trials methodology
  • Integration of diagnosis with therapy
  • Prediction of adverse reactions of drugs and drug safety
  • Treatment monitoring

Articles are subject to peer-review by three independent referees on a double-blind basis. Authors publishing in the journal are asked to disclose any professional or financial interest that may be perceived as causing a conflict of interest in the context of the article.

The journal welcomes unsolicited article proposals.

Contact Information

Subscription Information

Reprints & Supplements

Editorial Advisory Board

Indexing Information

Author Guidelines

Journal Information